Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP reduced its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 26.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 900,000 shares of the company's stock after selling 325,000 shares during the quarter. Aquestive Therapeutics makes up 0.8% of Blue Owl Capital Holdings LP's portfolio, making the stock its 26th biggest position. Blue Owl Capital Holdings LP owned approximately 0.99% of Aquestive Therapeutics worth $3,204,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of AQST. Price T Rowe Associates Inc. MD lifted its position in Aquestive Therapeutics by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after purchasing an additional 3,821 shares during the last quarter. Bracebridge Capital LLC lifted its position in Aquestive Therapeutics by 7.2% in the 4th quarter. Bracebridge Capital LLC now owns 459,216 shares of the company's stock valued at $1,635,000 after purchasing an additional 30,645 shares during the last quarter. Stifel Financial Corp lifted its position in Aquestive Therapeutics by 315.4% in the 4th quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock valued at $1,419,000 after purchasing an additional 302,617 shares during the last quarter. MetLife Investment Management LLC lifted its position in Aquestive Therapeutics by 11.4% in the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company's stock valued at $143,000 after purchasing an additional 4,125 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Aquestive Therapeutics in the 4th quarter valued at about $198,000. 32.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Lake Street Capital cut their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of "Buy" and an average price target of $10.67.

Aquestive Therapeutics Stock Up 1.6 %

NASDAQ AQST traded up $0.05 on Tuesday, reaching $2.88. 401,539 shares of the stock traded hands, compared to its average volume of 1,514,541. The firm's fifty day simple moving average is $2.78 and its 200 day simple moving average is $3.59. The company has a market cap of $284.25 million, a price-to-earnings ratio of -6.39 and a beta of 2.59. Aquestive Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts' expectations of $13.11 million. As a group, equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.